Table 1: Characteristics of landmark studies included in the systematic review and meta-analysis evaluating the prognostic and therapeutic implications of the WHO 2021 molecular classification of adult diffuse gliomas. Studies shown represent major randomized trials and molecular cohort investigations that substantially contributed to the evidence base supporting integrated molecular diagnosis and prognostic stratification. Most studies reported outcomes according to molecular biomarkers incorporated within the WHO 2021 classification framework, including IDH mutation status, 1p/19q codeletion, CDKN2A/B homozygous deletion, MGMT promoter methylation, TERT promoter mutation, EGFR amplification, and chromosome +7/-10 alterations.
|
Study |
Year |
Country |
Study Design |
Sample Size (n) |
Molecular Marker |
Median Follow-up (months) |
|
Eckel-Passow, et al. |
2015 |
USA |
Retrospective Cohort |
1087 |
IDH, 1p/19q, TERT |
74 |
|
Ceccarelli, et al. |
2016 |
International |
Genomic Cohort |
1122 |
Multi-marker |
68 |
|
Buckner, et al. (RTOG 9802) |
2016 |
USA |
RCT |
251 |
IDH, 1p/19q |
11.9 years |
|
Cairncross et al. (RTOG 9402) |
2013 |
USA |
RCT |
291 |
1p/19q |
16 years |
|
Van den Bent, et al. (EORTC 26951) |
2013 |
Europe |
RCT |
368 |
1p/19q |
12 years |
|
Van den Bent, et al. (CATNON) |
2021 |
International |
RCT |
751 |
IDH |
55 |
|
Shirahata, et al. |
2018 |
Germany |
Retrospective Cohort |
824 |
CDKN2A/B |
63 |
|
Johnson, et al. |
2014 |
USA |
Genomic Cohort |
114 |
IDH |
48 |
|
TCGA Consortium |
2015 |
International |
Genomic Database |
293 |
Multi-marker |
60 |
|
Weller, et al. |
2021 |
Europe |
Prospective Cohort |
547 |
WHO 2021 markers |
50 |